Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma – An external validation study-Reference-Cited by-同舟云学术

Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma – An external validation study

Published:2021-09 Issue:6 Volume:21 Page:1081-1091
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Henriksen Stine D.,Stubbe Benjamin E.,Madsen Poul H.,Johansen Julia S.,Jensen Benny V.,Hansen Carsten P.,Johansen Martin N.,Pedersen Inge S.,Krarup Henrik^ORCID,Thorlacius-Ussing Ole

Funder

Aalborg University Hospital

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference37 articles.

1. Cancer statistics, 2020;Siegel;CA A Cancer J Clin,2020

2. Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens;Haab;PLoS One,2015

3. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy;Hartwig;Ann Surg Oncol,2013

4. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma;Henriksen;Clin Epigenet,2016

5. DNA hypermethylation as a blood-based marker for pancreatic cancer: a literature review;Henriksen;Pancreas,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined ultrasound endoscopy-guided fine-needle aspiration with DNA methylation of SHOX2 and RASSF1A genes to enhance the auxiliary diagnostic precision of pancreatic cancer;Heliyon;2024-07

2. Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study;Cancer Medicine;2023-10

3. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma;Pancreatology;2023-08

4. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma;Frontiers in Oncology;2023-06-02

5. Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?;Cancers;2022-07-15